Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.49 |
| ▸ | JAK1 | P23458 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | TYK2 | P29597 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25280812 | 0.83 | JAK1 (0.55) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL16249700 | 0.81 | GPR119 (0.44) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL22576086 | 0.80 | JAK2 (0.49) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL30456898 | 0.80 | JAK2 (0.49) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL16249699 | 0.80 | PTPN11 (0.52) | GPR119MAPTDDB1CRBN | |
| SCHEMBL25229581 | 0.78 | JAK2 (0.49) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL22734993 | 0.77 | JAK1 (0.58) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL30501963 | 0.77 | JAK1 (0.58) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL22576307 | 0.77 | JAK1 (0.57) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL30501968 | 0.77 | JAK1 (0.57) | GPR119JAK1JAK2TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111511744-B | Diazaindole compounds | 百时美施贵宝公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11299501-B2 | Diazaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3728264-B1 | DIAZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3728264-B1 | DIAZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3728264-A1 | DIAZAINDOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200308195-A1 | DIAZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200308195-A1 | DIAZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | disclosed |
| CN-111511744-A | Diazaindole compounds | 百时美施贵宝公司 | 2020-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308195-A1 | DIAZAINDOLE COMPOUNDS | TLR7, TLR9, TLR1 | GPR119 17/4885JAK1 417/4885JAK2 164/4885 |
| US-11299501-B2 | Diazaindole compounds | TLR7, TLR9, TLR1 | GPR119 17/4885JAK1 417/4885JAK2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.